HIV Infections Clinical Trial
Official title:
A Clinical Trial to Establish The Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy
Malaria is a major contributor of disease burden in Sub-Saharan Africa: 90% of global cases
occur there, and pregnant women and children under 5 years are the most vulnerable. Malaria
in pregnancy increases risks of abortion, stillbirth, prematurity, intrauterine growth
retardation and maternal anemia, and is associated with higher risk of low birth weight and
perinatal, neonatal and infant mortality. For prevention and control of malaria in
pregnancy, the WHO recommends Intermittent Preventive Treatment (IPT) with antimalarial
drugs, insecticide treated nets (ITNs) and effective treatment of malaria and anemia.
HIV in pregnancy increases the risks of malaria, and it seems that the efficacy of IPT with
the drug sulphadoxine-pyrimethamine (SP) is decreased in HIV+ pregnant women.
Malaria prevention in pregnancy in Zambia relies on ITNs and IPT with SP. Daily prophylaxis
with cotrimoxazole (CTX) effectively reduces mortality and morbidity in HIV+ individuals,
and antibiotic therapy during pregnancy might help to decrease adverse pregnancy outcomes.
CTX prophylaxis improves birth outcomes in HIV+ women with CD4<200/µl: a study concluded
that antenatal provision of CTX was beneficial for HIV+ pregnant women with low CD4 but not
in women with ≥200/µl (however, this study was carried out in an area with very low risk of
malaria , and CTX may have a different effect depending on endemic conditions). The WHO
recommends daily CTX in addition to ARVs, to prevent opportunistic infections in all HIV+
patients.
Concurrent administration of SP and CTX may increase the incidence of severe adverse
reactions in HIV+ patients, so WHO has promoted CTX prophylaxis as an alternative to SP for
the IPT in immuno-compromised pregnant women. Unfortunately, there is insufficient
information on the effectiveness of daily CTX for preventing malaria infection in pregnancy:
so, SP is still the only antimalarial recommended by WHO for this purpose. With the increase
in SP resistance and with the newer antimalarials still being studied for safety and
efficacy in pregnancy, CTX could be an alternative for SP in reducing malaria and
malaria-related morbidity and mortality in pregnancy.
This study will try to to see if in HIV- and HIV+ pregnant women, CTX is not inferior to SP
in reducing placental parasitaemia. Such information is needed to issue updated, effective
guidelines on malaria prevention in pregnancy
Status | Completed |
Enrollment | 848 |
Est. completion date | February 2013 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Confirmed pregnancy (through palpable fundus and/ or positive pregnancy test) - Gestational age between 16 and 28 weeks - Hb > 7 g/dl, by Hemocue - No symptoms consistent with malaria - Residence within the health facility catchment's area - Willingness to deliver at the health facility - Willingness to adhere to all requirements of the study (including HIV-1 voluntary counselling and testing) - Ability to provide written informed consent. If the woman is a minor of age/not emancipated, the consent must be given by a parent or legal guardian according to national law (however, in this case, also the minor woman will sign the consent form, to document that she is freely giving her assent to take part in the study). Exclusion Criteria: - History of allergy to study drugs, or previous history of allergy to sulpha drugs - History or presence of major illnesses likely to influence pregnancy outcome including diabetes mellitus, severe renal or heart disease, or active tuberculosis - Any significant illness at the time of screening that requires hospitalization - Intent to move out of the study's catchment area before delivery or deliver at relative's home out of the catchment's area; - Prior enrolment in the study or concurrent enrolment in another study - Severe anaemia (Hb<7 g/dl) - Previous history of unfavourable pregnancy outcome: pre-eclampsia, caesarean section, stillbirth. - Eligible HIV-positive women who, following the National guidelines, have to be put on CTX prophylaxis (e.g. having a CD4 count <350/µl) or already on CTX and/or ARV treatment will be excluded from the RCT but included in a prospective observational cohort and receive 2 tablets of CTX daily |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Zambia | Kabuta Health Centre | Kabuta | Nchelenge District, Luapula Province of |
Lead Sponsor | Collaborator |
---|---|
Institute of Tropical Medicine, Belgium | Tropical Diseases Research Centre, Zambia |
Zambia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To establish that in HIV negative pregnant women co-trimoxazole prophylaxis is non inferior to SP IPT with respect to birth weight at delivery (or within 24 hours). Non inferiority is defined as a difference in mean birth weights of no more than 100g. | Up to the end of pregancy | No | |
Secondary | To evaluate the effectiveness of co-trimoxazole prophylaxis and SP IPT in reducing placenta malaria in HIV+ pregnant women with CD4 = 350/µl and in the combined group of HIV- and HIV+ pregnant women with CD4 = 350/µl | Up to the end of pregnancy | No | |
Secondary | To evaluate the effectiveness of CTX and SP IPT in reducing malaria peripheral infection, in HIV negative, and in HIV positive pregnant women with a CD4 cell count = 350/µl | Up to the end of pregnancy | No | |
Secondary | To evaluate the effect of CTX and SP IPT on the offspring by measuring the gestational age at delivery, perinatal mortality and birth weight, in HIV negative pregnant women and in HIV positive pregnant women with a CD4 cell count = 350/µl | At delivery | Yes | |
Secondary | To compare the effectiveness and safety profiles of CTX prophylaxis to that of SP IPT, in HIV negative pregnant women and in HIV positive pregnant women with a CD4 cell count = 350/µl | Up to the end of pregancy | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |